Studies from Agharkar Research Institute Have Provided New Data on siRNA-Based Therapy (MUC1 aptamer-tethered H40-TEPA-PEG nanoconjugates for targeted siRNA-delivery and gene silencing in breast cancer cells).

A recent report from the Agharkar Research Institute in Pune, India, discusses the potential of siRNA-based therapy for breast cancer treatment. Breast cancer is the most common form of cancer worldwide, and current therapies are limited in their effectiveness. The researchers developed an aptamer-conjugated dendritic multilayered nanoconjugate to target breast cancer cells. Their experiments showed that the targeted dendrimers successfully inhibited the expression of the target gene in breast cancer cells and induced apoptosis. This research suggests that siRNA-based therapy could be a promising approach for treating breast cancer. [Extracted from the article]